Physicochemical Properties
| Molecular Formula | C20H20CLN7O5S4 |
| Molecular Weight | 602.11 |
| Exact Mass | 601.01 |
| Elemental Analysis | C, 39.90; H, 3.35; Cl, 5.89; N, 16.28; O, 13.29; S, 21.30 |
| CAS # | 189448-35-9 |
| PubChem CID | 9873517 |
| Appearance | Solid powder |
| LogP | 3.04 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 10 |
| Heavy Atom Count | 37 |
| Complexity | 975 |
| Defined Atom Stereocenter Count | 2 |
| SMILES | NCCSCC1C=NC=CC=1SC1CSC2C(C(=O)N2C=1C(=O)O)NC(/C(/C1N=C(N)SC=1Cl)=N/O)=O |
| InChi Key | LTUWUNMGTLOPNC-RLQAYIIJSA-N |
| InChi Code | InChI=1S/C20H20ClN7O5S4/c21-15-11(26-20(23)37-15)12(27-33)16(29)25-13-17(30)28-14(19(31)32)10(7-35-18(13)28)36-9-1-3-24-5-8(9)6-34-4-2-22/h1,3,5,13,18,33H,2,4,6-7,22H2,(H2,23,26)(H,25,29)(H,31,32)/b27-12-/t13-,18-/m1/s1 |
| Chemical Name | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-5-chloro-4-thiazolyl)(hydroxyimino)acetyl)amino)-3-((3-(((2-aminoethyl)thio)methyl)-4-pyridinyl)thio)-8-oxo-, (6R-(6alpha,7beta(Z)))- |
| Synonyms | RWJ-54428; RWJ 54428; RWJ54428; MC02479; MC-02479; MC 02479 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References | 1: Malouin F, Blais J, Chamberland S, Hoang M, Park C, Chan C, Mathias K, Hakem S, Dupree K, Liu E, Nguyen T, Dudley MN. RWJ-54428 (MC-02,479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP 2a, and stability to staphylococcal beta-lactamases. Antimicrob Agents Chemother. 2003 Feb;47(2):658-64. doi: 10.1128/AAC.47.2.658-664.2003. PMID: 12543674; PMCID: PMC151748. 2: Griffith DC, Harford L, Williams R, Lee VJ, Dudley MN. In vivo antibacterial activity of RWJ-54428, a new cephalosporin with activity against gram-positive bacteria. Antimicrob Agents Chemother. 2003 Jan;47(1):43-7. doi: 10.1128/AAC.47.1.43-47.2003. PMID: 12499167; PMCID: PMC149000. 3: Griffith DC, Rodriguez D, Corcoran E, Dudley MN. Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a neutropenic mouse thigh infection model. Antimicrob Agents Chemother. 2008 Jan;52(1):244-7. doi: 10.1128/AAC.00776-07. Epub 2007 Oct 22. PMID: 17954697; PMCID: PMC2223871. 4: Chamberland S, Blais J, Hoang M, Dinh C, Cotter D, Bond E, Gannon C, Park C, Malouin F, Dudley MN. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria. Antimicrob Agents Chemother. 2001 May;45(5):1422-30. doi: 10.1128/AAC.45.5.1422-1430.2001. PMID: 11302805; PMCID: PMC90483. 5: Johnson AP, Warner M, Carter M, Livermore DM. In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant gram-positive cocci. Antimicrob Agents Chemother. 2002 Feb;46(2):321-6. doi: 10.1128/AAC.46.2.321-326.2002. PMID: 11796337; PMCID: PMC127043. 6: Hecker SJ, Glinka TW, Cho A, Zhang ZJ, Price ME, Chamberland S, Griffith D, Lee VJ. Discovery of RWJ-54428 (MC-02,479), a new cephalosporin active against resistant gram-positive bacteria. J Antibiot (Tokyo). 2000 Nov;53(11):1272-81. doi: 10.7164/antibiotics.53.1272. PMID: 11213288. 7: Swenson JM, Tenover FC. In vitro activity of a new cephalosporin, RWJ-54428, against streptococci, enterococci and staphylococci, including glycopeptide- intermediate Staphylococcus aureus. J Antimicrob Chemother. 2002 May;49(5):845-50. doi: 10.1093/jac/dkf020. PMID: 12003982. 8: Lee VJ, Hecker SJ. Antibiotic resistance versus small molecules, the chemical evolution. Med Res Rev. 1999 Nov;19(6):521-42. doi: 10.1002/(sici)1098-1128(199911)19:6<521::aid-med4>3.0.co;2-9. PMID: 10557368. 9: Hoffman-Roberts HL, C Babcock E, Mitropoulos IF. Investigational new drugs for the treatment of resistant pneumococcal infections. Expert Opin Investig Drugs. 2005 Aug;14(8):973-95. doi: 10.1517/13543784.14.8.973. PMID: 16050791. 10: Hoellman DB, Kelly LM, Jacobs MR, Appelbaum PC. In vitro anti-anaerobic activity of the cephalosporin derivative RWJ 54428, compared to seven other compounds. Clin Microbiol Infect. 2002 Dec;8(12):814-22. doi: 10.1046/j.1469-0691.2002.00475.x. PMID: 12519357. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6608 mL | 8.3041 mL | 16.6083 mL | |
| 5 mM | 0.3322 mL | 1.6608 mL | 3.3217 mL | |
| 10 mM | 0.1661 mL | 0.8304 mL | 1.6608 mL |